VITA HEALTH PRODUCTS INC - Rezultatele cautarii

ceva sante animale - Вирус е инфекциозно бурсальной болест (ibdv), в щата Масачузетс щам Н-120; вирус Ньюкаслской болест (НДВ), прецедете ниво phy.ЛМВ.42 - таблетка - мин. 10 на 5,5 степен eid50; мин. 10 на 3,3 степен eid50 - пилета

Bulgaria - bulgară - БАБХ (Българска агенция по безопасност на храните)

apiguard gel гел

vita bee health limited - Тимол - гел - 12.5 g / 50.0 g ± 5 % - пчели

Uniunea Europeană - bulgară - EMA (European Medicines Agency)

clopidogrel viatris (previously clopidogrel taw pharma)

viatris limited - клопидогрел безилат - peripheral vascular diseases; stroke; myocardial infarction - Антитромботични агенти - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). Възхода на сегмента st остър инфаркт на миокарда, в комбинация с ВЪЗХОДЯЩО в лечението на пациенти, които имат право на тромболитической терапия. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. За повече информация, моля, вижте раздел 5.